Risk of Hepatitis B from Blood Transfusion
The current risk of acquiring hepatitis B from a blood transfusion in the United States is extremely low, estimated at approximately 1 in 282,000 to 1 in 357,000 transfused blood components (approximately 2.8 to 3.6 per million transfusions). 1
Modern Screening Has Made Transfusion-Transmitted HBV Exceptionally Rare
The dramatic reduction in transfusion-transmitted hepatitis B represents one of the major safety achievements in transfusion medicine. Transmission of HBV by transfusion is now rare due to routine screening of blood donors for HBsAg and current donor selection procedures. 2
Historical Context Shows Remarkable Progress
The evolution of blood safety demonstrates the effectiveness of current screening:
- Pre-1970: Approximately 6% of multi-transfused recipients acquired HBV—a risk of roughly 1 in 17 3
- Early screening (1970s): Using first-generation tests, 52-69% of recipients of HBsAg-positive blood developed hepatitis B 2
- Mid-1970s: With third-generation tests and volunteer donors, risk reduced to 0.3-0.9% per transfusion recipient 2
- Late 1980s: Risk estimated at 0.002% per transfusion recipient 2
- Current era (2006-2008): Risk of 1 in 282,000 to 357,000 per blood component 1
This represents a greater than 1000-fold improvement in safety over 50 years 3.
Why Residual Risk Persists: Occult HBV Infection
Despite highly sensitive screening (>99% sensitivity for HBsAg), a small residual risk remains because:
A small number of HBV carriers circulate HBsAg at undetectable levels, with anti-HBc potentially being the only detectable serologic marker 2. These occult HBV infections (OBI) may have:
- Extremely low viral DNA levels that are intermittently or not detectable even by highly sensitive individual donation nucleic acid testing (ID-NAT)
- Viral loads below 200 virions that can still occasionally transmit infection 4
Models estimate a residual transmission risk of 3-14% associated with OBI donations that test negative for both HBsAg and ID-NAT 4. However, actual transmission depends on multiple factors including the plasma volume transfused, the recipient's anti-HBV immune status, and the viral fitness of the infecting strain.
Comparative Risk Perspective
To contextualize this risk, the 2012 AABB guidelines provide useful comparisons 1:
- HBV transfusion risk: 2.8-3.6 per million transfusions
- HIV transfusion risk: 6.8 per 10 million transfusions (lower than HBV)
- HCV transfusion risk: 8.7 per 10 million transfusions (lower than HBV)
- Fatal hemolytic reaction: 8 per 10 million RBC units
- Lightning strike death: 0.02-2.0 per million persons annually
HBV remains the highest residual viral risk in blood transfusion, though still extraordinarily low in absolute terms.
Clinical Implications
When a patient develops hepatitis B following transfusion:
- Do not automatically assume transfusion transmission—the background rate of HBV acquisition in the general population now exceeds transfusion risk 5
- Investigate other exposure routes: sexual contact, household exposure, percutaneous exposures, healthcare-related exposures 2
- Consider timing: HBsAg appears 30-60 days post-exposure 2
Important Caveats
- These risk estimates apply to screened blood from volunteer (unpaid) donors in developed countries with robust screening programs
- Risk varies by geographic region based on HBV prevalence and screening infrastructure
- Anti-HBc screening (implemented 1986-1987) may have contributed to further risk reduction, though most decline occurred before its implementation due to improved donor selection related to HIV prevention 2
The current safety of the blood supply means that other modes of HBV transmission should be thoroughly investigated before attributing hepatitis B to a recent transfusion.